KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Finished Goods (2016 - 2025)

Edwards Lifesciences (EW) has 12 years of Finished Goods data on record, last reported at $676.7 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 11.04% year-over-year to $676.7 million; the TTM value through Dec 2025 reached $676.7 million, up 11.04%, while the annual FY2025 figure was $676.7 million, 11.04% up from the prior year.
  • Finished Goods reached $676.7 million in Q4 2025 per EW's latest filing, up from $642.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $676.7 million in Q4 2025 and bottomed at $511.4 million in Q4 2023.
  • Average Finished Goods over 3 years is $610.9 million, with a median of $611.0 million recorded in 2024.
  • Peak YoY movement for Finished Goods: rose 19.16% in 2024, then fell 11.1% in 2025.
  • A 3-year view of Finished Goods shows it stood at $511.4 million in 2023, then grew by 19.16% to $609.4 million in 2024, then grew by 11.04% to $676.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $676.7 million in Q4 2025, $642.2 million in Q3 2025, and $630.5 million in Q2 2025.